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Acute rheumatic fever and rheumatic heart disease are noninfectious sequelae of group A streptococcal pharyngeal
infection. These diseases represent a huge public health burden in developing countries with signiﬁcant mortality
and morbidity. Early diagnosis and appropriate antibiotic treatment with group A streptococcal pharyngitis
provides an opportunity for prevention of acute rheumatic fever and rheumatic heart disease. The use of locally
adapted clinical algorithms for diagnosing group A streptococcal pharyngitis has great potential in resource-poor
settings for earlier diagnosis and early treatment. Intramuscular penicillin is the drug of choice in developing
country settings. Recent work has demonstrated the cost-effectiveness of a treat-all strategy with intramuscular
penicillin, whereas incorporating a clinical decision rule remains the preferred strategy. We strongly support the
adoption of a comprehensive prevention and control program for acute rheumatic fever and rheumatic heart
disease, incorporating primary prevention, as critical to underpinning the efforts in many parts of the world to
stem the tide of this devastating disease.L. Zühlke is funded by the
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CC BY-NC-ND license.Acute rheumatic fever (ARF) and rheumatic heart disease
(RHD) continue to kill children, adolescents, and young
adults living in poverty. Yet, a cheap and effective preventative
agent to these sequelae of group A streptococcal (GAS)
infection has existed for decades in the form of penicillin.
Despite strong evidence of penicillin’s efﬁcacy in primary
prevention of ARF, debate still rages on regarding the appro-
priate role for primary preventionwithinRHDprevention and
control strategies. Some of the arguments against the incor-
poration of primary prevention into RF/RHD control strate-
gies are based on the expense and logistics of delivery, but as
has been discussed elsewhere [1], these need not be limiting
factors. Conversely, a recent publication has demonstrated the
cost-effectiveness of such a strategy [2]. More importantly,
these arguments serve, unwittingly, to undermine the role of
primary prevention in the control of RHD.
BURDEN OF DISEASE
Group A streptococcal disease
GAS has been studied for decades and is a well-known
pathogen. It is responsible for over 600 million infections
annually, ranging from self-limiting pharyngitis to invasive
and life-threatening toxic shock syndrome and necrotizing
fasciitis [3]. The global burden of severe GAS infections has
been estimated to be as high as 18.1 million cases with
1.78 million new cases a year and over 500,000 deaths
each year [4]. This predominantly occurs in developing
countries and poor subpopulations within middle- and
high-income countries (such as the indigenous populations
of Australia and New Zealand). Although long ignored as a
disease of the developing world, the recent resurgence of
invasive disease in developed countries [5], coupled withGLOBAL HEART, VOL. 8, NO. 3, 2013
September 2013: 221-226evidence of hypervirulent strains has resulted in increased
academic interest and activities relating to vaccine devel-
opment. This has also highlighted the many unknowns
relating to this organism, especially in terms of pathoge-
nicity, distribution of isolates, and virulence factors.Acute rheumatic fever and rheumatic heart
disease
ARF is the systemic noninfectious sequel to the often self-
limiting pharyngitis caused by rheumatogenic strains of
GAS. The only permanent and devastating sequel to ARF is
RHD, for which no proven treatment exists to alter the
natural history of the disease. ARF has shown a dramatic
decrease in incidence in developed countries, with
increasing standards of living and access to health care being
the major determinants of this change [6]. In developing
countries, this pattern is following a similar thoughmarkedly
attenuated trend. A systematic review [7] of studies reporting
incidence of ARF conducted in 2008 still demonstrated a
high incidence (>10 per 100,000) in poorer regions of
Eastern Europe, Middle East (highest), Asia, and Australasia,
while no data could be included for Africa. A more recent
reviewwas able to include data from Sub-Saharan Africa and
recorded the highest incidence in the Western Paciﬁc and
Asia [8]. Mortality due to ARF relates strongly to differences
in health care with higher case fatality rates in developing as
opposed to developed countries.
In contrast, the prevalence of RHD appears to be
increasing. Seckeler et al. [8] were able to show this trend
through almost all the World Health Organization regions
of the world except for Europe. Given the decreasing
incidence of ARF, this is most likely due to advances in221
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increased survival. Most importantly, the diagnosis of RHD
has also become more rigorous with the use of echocar-
diography. The increased sensitivity of echocardiography
has resulted in rates that are 10-fold that of RHD diagnosed
by auscultation alone [9]. Vital registration data have
determined that mortality rates from RHD follow the same
pattern as that for ARF: highest in developing countries,
although high-quality mortality data are lacking from Sub-
Saharan Africa [10]. The highest case fatality rate for RHD
was recorded in Pakistan at 3.7 per 100,000 [10]. Clearly,
it is irrefutable that the highest burden of disease for both
ARF and RHD lies in developing countries with concom-
itant high mortality rates. What is also clear is that in the
absence of a cure for RHD, and being cognizant of the
limited health resources of developing countries, our focus
should turn toward effective prevention.
RATIONALE FOR PRIMARY PREVENTION
Pharyngitis is a common childhood illness with up to 26%
of these infections being caused by GAS [11]. ARF is
thought to occur in 0.3% to 3% of individuals infected
with GAS as an autoimmune response to the initial infec-
tion. Controversy remains regarding the role of GAS in-
fections other than pharyngitis [12]. There is anecdotal
evidence for the potential role of skin infections, particu-
larly in the Australian Aboriginal population, yet this re-
mains circumstantial and as yet unproven in other
populations [13e15]. What is clear is that GAS infection is
causally related to the development of ARF, as is evidenced
by outbreaks of GAS pharyngitis followed by outbreaks of
ARF and the increased antistreptococcal antibodies found
in patients with ARF [16]. Primary prevention strategies
focus on the early diagnosis and timely treatment of GAS
pharyngitis with antibiotics to prevent the autoimmune
consequences resulting from the infection in susceptible
individuals. It is thought that antibiotic therapy initiated
within 9 days of onset of pharyngitis is effective in pre-
venting ARF [17].
EVIDENCE FOR PRIMARY PREVENTION
The value of primary prevention has been known as early
as the 1950s when randomized control trials demonstrated
that ARF could be prevented by treating GAS pharyngitis
with penicillin. Research conducted among army personnel
demonstrated proof of effectiveness of primary antibiotic
prophylaxis as a strategy for high-risk populations [18].
This was followed by successful programs such as the
Baltimore-based program that demonstrated a 50-fold drop
in ARF incidence 15 years after instituting a comprehensive
prevention program focusing on the diagnosis and treat-
ment of streptococcal sore throats in inner-city children
[19]. A report from the House of the Good Samaritan,
Boston, noted that although mortality due to rheumatic
carditis had been steadily declining in the United States
since about 1921, a 4-fold acceleration of the declineoccurred after 1945, the approximate time when penicillin
began to be widely used for streptococcal pharyngitis [20].
A systematic review of hospital-based primary inter-
vention strategies evaluated the effectiveness of antibiotics
in preventing ARF and was able to determine a substantial
protective effect using pooled meta-analysis of randomized
and quasi-randomized trials. In patients with a sore throat
and symptoms suggestive of GAS infection, antibiotic
treatment reduced the risk of ARF by 70% and by 80%
when intramuscular penicillin was used [21]. The sub-
group analysis, focusing on the group treated with intra-
muscular penicillin, yielded a number needed to treat
of 60.
IMPORTANT CASE STUDIES
Like the hospital-based programs, community efforts such
as those in Cuba, Costa Rica, and Martinique have also
shown remarkable success and have resulted in the virtual
elimination of ARF using comprehensive, integrated pro-
grams targeting primary and secondary prevention [22,23].
These 10-year programs were able to demonstrate a
reduction in ARF in Martinique and Guadeloupe of 78%
and 72%, respectively and from 18.6 per 100,000 to 2.5 per
100,000 in Cuba. These were both comprehensive com-
munity interventions, consisting of awareness campaigns,
establishment of registries and medical training with
particular emphasis on primary and secondary prevention.
Both these programs resulted in dramatic declines in direct
costs (86% in both Cuba and Martinique). Although it is
difﬁcult to tease out which speciﬁc component was pri-
marily responsible for the rapid decrease in incidence of
ARF, it does provide convincing evidence that a strategy
that includes primary prevention can be markedly effective.
COST OF PRIMARY PREVENTION
In the resource-limited areas where ARF and RHD are most
rife, the importance of cost analyses cannot be over-
estimated. The cost of chronic RHD treatment has been
estimated at US$319 per patient per year, whereas an open
heart operation would cost anywhere from US$35,000 to
US$50,000 [24]. In Brazil, it was estimated in 2001 that
the chronic care costs for a patient with ARF could
constitute as much as 1.3% of annual family income. As
ARF and RHD are intimately related to poverty, this eco-
nomic burden is unsustainable for the countries and peo-
ple involved. Yet the cost of the prevention program in
Martinique was a fraction of the cost of cardiac surgery:
US$44,500 per year for the program compared with
US$654,000 for open-heart surgery [23]. This is also the
case in more recent comprehensive RHD control programs,
which have been run for only a fraction of the cost of
performing heart valve surgery on severe RHD patients
[25]. Until recently, the costs of a focused primary pre-
vention strategy were thought to be prohibitive [26].
However, Irlam et al. [2] described a cost-effective analysis
of various strategies for the primary prevention of ARF inGLOBAL HEART, VOL. 8, NO. 3, 2013
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an urban primary healthcare clinic. Using a Markov model,
they were able to determine that a treat-all strategy using
intramuscular penicillin was the least costly, whereas the
strategy of incorporating a clinical decision rule is overall the
preferred strategy. This landmark study reinforced the belief
that culturing all children with pharyngitis was prohibitively
expensive in developing country settings [2].
OBSTACLES TO EFFECTIVE PRIMARY PREVENTION
Taranta and Gordis [27] described prevention for RHD, in
the face of no cure, as “not only desirable but essential.” They
did acknowledge, though, the inherent difﬁculties associated
with the accurate diagnosis and treatment of streptococcal
pharyngitis in the general population. Signiﬁcant barriers to
the adequate diagnosis and treatment of streptococcal
pharyngitis and thus primary prevention remain namely: 1)
the diagnosis of GAS pharyngitis; 2) treatment options and
concerns; 3) patient and physician awareness; and 4) the
positioning of primary prevention within a control program.
Diagnosis of GAS pharyngitis
The gold standard conﬁrmatory test for streptococcal
pharyngitis is largely accepted to be a pharyngeal swab cul-
ture that is positive for GAS [28]. Ofﬁce pediatricians in
developed countries make use of rapid strep tests to make
this diagnosis. However, there are very few countries in
highly affected regions of the world utilizing routine rapid
antigen or microbiological testing due to the cost involved.
Furthermore, the delay involved in awaiting results of cul-
ture before a diagnosis can be made will result in missed
diagnoses and tragic consequences. Finally, rapid antigen
detection tests, although demonstrating positive results [29],
should be tested within the local setting prior to advocating
their use. The use of a locally adapted, risk stratiﬁed, clinical
prediction rules such as those used in New Zealand and
Cuba [22,30,31] offers a different approach to detect GAS
pharyngitis. A recent pragmatic scoring system tested in
Brazil was able to demonstrate a receiver-operator charac-
teristic curve of 0.66 (95% conﬁdence interval: 0.62 to 0.71)
and allowed for signiﬁcant (35% to 55%) sparing of antibi-
otic prescriptions while still maintaining an 88% speciﬁcity
[32]. This is in stark contrast with the World Health Orga-
nization prediction rule, whichmissed up to 96%of children
with positive cultures when applied to children in poorer
settings [33]. Clinical prediction rules thus do run the risk of
over- or underdiagnosis. However, this risk is substantially
decreased when algorithms incorporating local ARF pre-test
risk factors are applied. This will improve correct diagnosis
of GAS sore throat while keeping unnecessary antibiotic
usage to a minimum.
Treatment options and concerns
The current treatment guidelines for GAS pharyngitis were
revised in 2009 and are detailed in Table 1 [17]. The
American Heart Association has recommended penicillin
V or amoxicillin as ﬁrst-choice antibiotics, followed byGLOBAL HEART, VOL. 8, NO. 3, 2013
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penicillin as ﬁrst-line treatment is scant. Given that the few
trials testing the efﬁcacy of penicillin for preventing ARF
were limited to intramuscular (as opposed to oral) penicillin
[34,35], our recommendation is that intramuscular peni-
cillin should be the ﬁrst choice in keeping with the evidence.
This will also result in better compliance [21]. However,
there are problems with both the consistency of supply and
quality of benzathine penicillin G around the world. There
are a number of studies documenting that different batches
from suppliers may have variable pharmacokinetic proper-
ties, and the batches may vary physically, resulting in un-
reliable serum penicillin levels [36e40]. Benzathine
penicillin G is on the Core List of Essential Medicines for
developing countries, so it is critical that we ﬁnd a solution to
this problem. Patients treated with oral penicillin are advised
to complete a 10-day course and pediatric solutions need to
be kept refrigerated. This clearly is highly problematic in the
countries in question and has resulted in lack of concordance
with treatment regimes. In addition, reluctance on behalf of
patients due to the associated pain from an intramuscular
injection and practitioners relating to concerns regarding
anaphylaxis must be taken into consideration. The use of
intramuscular penicillin must be balanced against the risk of
incomplete oral regimes for GAS pharyngitis and local
quality and supply of intramuscular penicillin.Patient and community awareness
In a study from Dar Es Salaam, Tanzania, the following
barriers to the diagnosis and treatment of GAS pharyngitis
were identiﬁed: 1) that patients do not present for treat-
ment of sore throat; and 2) that there is little patient and
community knowledge regarding the importance of treat-
ing a sore throat. In addition, the concomitant lack of
awareness of primary prevention had resulted in a lack of
prioritization of GAS screening and treatment [41].
Even RHD patients themselves uniformly stated that
they would not take their children with a sore throat to
professional healthcare providers. Cost and travel to a
district-level clinic was a major factor in their decision
making, a factor that was also in a report from Jimma,
Ethiopia [42]. A concerningly high level of ignorance
around the causality of ARF and RHD was encountered in
this and other papers, with few of the respondents with
RHD questioned in a paper from South Africa knowing the
cause of ARF [43]. Patients had poor knowledge of the
connection between pharyngitis and RHD and preferred
local remedies or simple pain medication. Physicians in
these 3 studies were of the overwhelming opinion that
patients and their families were not aware about the con-
sequences of untreated GAS infection. Patients reported
little prior knowledge of ARF before their diagnosis, an
indication of the lack of community awareness of the dis-
ease. Physician awareness of the importance of sore throat
management was generally good, although respondents
indicated that screening patients with GAS might be seen223
TABLE 1. Primary prevention of rheumatic fever (treatment of streptococcal tonsillopharyngitis)
Agent* Dose Mode Duration
Penicillin
 Penicillin V Children: 250 mg 3 times daily for <27 kg
Adolescents and adults: 500 mg 2 to
3 times daily
Oral 10 days
 Amoxicillin 50 mg/kg once daily (maximum 1 g) Oral 10 days
 Benzathine
penicillin G
600,000 IU for patients 27kg
1,200,000 IU for patients >27 kg
Intramuscular Once
Allergic to penicillin
 Narrow-spectrum
cephalosporin
Variable Oral 10 days
 Clindamycin 20 mg/kg per day divided in 3 doses
(maximum 1.8g/d)
Oral 10 days
 Azithromycin 12 mg/kg once daily (maximum 500 mg) Oral 5 days
 Clarithromycin 15 mg/kg per day divided into 2 doses
(maximum 250 mg twice daily)
Oral 10 days
IU, international units.
*The following antibiotics are not acceptable: sulphonamides; trimethoprim; tetracyclines; and ﬂuoroquinolones.
Adapted from Gerber MA et al. [17].
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man immunodeﬁciency virus and malaria.Positioning of primary prevention within a control
program
There is international disagreement regarding the way in
which primary prophylaxis should be incorporated into
control strategies [1,44e46]. Everyone seems to be in
agreement that promotion of sore throat diagnosis and
treatment within existing primary healthcare systems is
important, although it is not clear how this should be
done. The particular role of systematic sore throat
screening and treatment programs in schools or commu-
nities is also contentious. The debate revolves around the
role of sore throat screening and treatment programs in
schools, with one side claiming that there is sufﬁcient ev-
idence to promote this approach and the other claiming
that the evidence of efﬁcacy, effectiveness, and cost-
effectiveness is insufﬁcient to recommend it [31,47]. We
believe that the existing evidence is insufﬁcient, that a more
deﬁnitive study would be logistically difﬁcult and expen-
sive, and, furthermore, that even if it were proven to be
effective, such a strategy would be difﬁcult to implement
and unaffordable in low-income countries [48]. Unlike the
school-based model, the community models from Cuba,
Costa Rica, and the islands of Martinique and Guadeloupe
represent the best evidence for integration. Here a
comprehensive strategy involving syndromic treatment of
suspected GAS pharyngitis with penicillin was introduced
and maintained for over 10 years. This was within a
concerted educational campaign that attempted to involve
and target the public, social, and educational professionals,
as well as healthcare workers at every level, in particular
those at primary care facilities. A media educationcampaign involving radio, television, and pamphlets
together with workshops and symposia for healthcare
workers ran throughout the period of the program and
stressed the benign presentation of sore throat and con-
trasted it with the severity of heart disease [22,23].
It is critical to be reminded that even in themost optimal
circumstances, as many as 60% of patients subsequently
diagnosed with ARF cannot recall a previous episode of sore
throat [49]. Therefore, it is crucial that the patients who do
present with sore throats, provide us with an important
opportunity for intervention that should not be missed.OPPORTUNITIES FOR PRIMARY PREVENTION
We are currently witnessing a surge in ARF and RHD
control activity largely driven from parts of the world
where ARF/RHD mostly occurs. Research, as well as public
health programs and political advocacy, are now centered
in developing countries and those subpopulations within
middle- and high-income countries where high burdens of
disease still exist. A real opportunity exists for dramatic
progress to occur toward the goal of “eradicating ARF and
RHD in our lifetime” [50,51].
Following up on the excellent work carried out in Cuba,
Costa Rica, and other countries, similar programs have now
evolved in several other sites, a world-leading program of
RHD control in Paciﬁc Island nations has individuals from
Tonga, Fiji, and Samoa at the helm, whereas the ASAP
(Advocacy, Surveillance, Awareness, and Prevention) pro-
gram, under the auspices of the Pan-African Society of Car-
diology has galvanized efforts in Africa to combat this disease
[52]. These programs all feature a comprehensive approach
combining education, awareness, and primary care man-
agement as key components [26,53e55]. Collaborations
between developing countries, such as India, Brazil, andGLOBAL HEART, VOL. 8, NO. 3, 2013
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South Africa, promise to yield important insights into un-
derstanding of the GAS antigenic processes and RF patho-
genesis and inform vaccine development [56].
These efforts have been met with renewed support from
global organizations such as the World Heart Federation,
which has made a major commitment to leading the charge
on RHD control, supporting programs in the Paciﬁc and
Africa, establishing an international web-based resource in
ARF/RHD, and, in their most recent strategic plan,
committing to “eliminating rheumatic fever and minimizing
the burden of rheumatic heart disease.” The World Heart
Federation also hosted the Postgraduate Course on Rheu-
matic Heart Disease: Challenges and Opportunities at the
Seventh Global Forum on Humanitarian Medicine in Car-
diology and Cardiac Surgery in Geneva, Switzerland. Not
only will this raise the proﬁle of ARF and RHD within the
medical community, but also the community at large,
through their partners and global alliances [57].
A major limitation of an integrated primary prevention
strategy relates to existing healthcare infrastructure, which is
grossly under-resourced and poorly serviced in the very
populations in which RF/RHD is rampant. The ever-
increasing need for skilled healthcare workers has led to the
formation of cadres of assistant medical ofﬁcers and task
shifting [58]. Using community health workers in integrated
primary health care, human immunodeﬁciency virus man-
agement has achieved much success in resource-limited
countries such as Haiti and Rwanda [59,60]. By integrating
treatment of sore throat into other programs, and the inno-
vative use of community health workers to strengthen the
program, in terms of treatment as well as education, similar
successes could be achieved.
SUMMARY
Rheumatic heart disease is unique among chronic cardio-
vascular diseases in several ways. It is entirely preventable.
It is among the few chronic cardiovascular diseases of
childhood, adolescence, and young adulthood, and it
straddles the silos of infectious and noncommunicable
diseases and, therefore, represents perfectly the needs of
developing countries in the 21st century, now dealing
increasingly with this double burden [61]. The potential
economic burden of chronic cardiovascular disease in the
developing world is overwhelming, and any opportunity to
prevent chronic disease should be embraced and strongly
advocated at the highest levels. We have presented the
progress made in primary prevention of acute rheumatic
fever, as well as listing some of the obstacles and oppor-
tunities in this ﬁeld. Primary prevention is the cornerstone
of any RHD program and integration into existing primary
care systems should be a priority.
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